Phrontline Biopharma

Phrontline Biopharma

Private
ShanghaiHealthcare & Life Scienceshttps://phrontlinebio.com

Last Round

pre_series_a_plus

Nov 25, 2025

Total Funding Raised

$74.03M

Momentum Score

50 /100

Company Overview

Phrontline Biopharma is a biotechnology company that develops innovative antibody-drug conjugates (ADCs) to address unmet medical needs in oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCbispecific ADCdual-payload ADConcology therapeuticssolid tumorsclinical-stage biotechprecision oncologybispecific antibodiescancer drug developmentpharma licensingnon-small-cell lung cancerNSCLClinker-payload engineeringtopoisomerase I inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phrontline Biopharma Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Phrontline Biopharma Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
pre_series_a_plusNov 25, 2025
Early FundingNov 24, 2025
Pre SeedDec 25, 2023

Phrontline Biopharma Investors

Notable investors and investment history

InvestorRounds
Jifeng VenturesEarly Funding, pre_series_a_plus
Medfine Health FundPre Seed, pre_series_a_plus
Lapam Capitalpre_series_a_plus
Decheng CapitalEarly Funding, Pre Seed, pre_series_a_plus
Samsung Venture InvestmentEarly Funding, pre_series_a_plus
C&D Emerging Industry Equity Investmentpre_series_a_plus
Medfine Capitalpre_series_a_plus

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 25, 2025

    Raised $60M in a pre-Series A+ round.

  • Oct 31, 2025

    Partnered with Sino Biopharmaceutical Limited for product TJ101 in China.

Phrontline Biopharma Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phrontline Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phrontline Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range5
Year Founded2022
Last FundingNov 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.